RG 6436
Alternative Names: GDC 0829; RG-6436Latest Information Update: 05 Mar 2024
At a glance
- Originator Enterprise Therapeutics
- Developer Genentech
- Class Antibacterials; Small molecules
- Mechanism of Action Type I signal peptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Urinary tract infections
Most Recent Events
- 21 Feb 2024 Phase-I clinical trials in Urinary tract infections (In volunteers) in USA (IV) (ISRCTN18049481)
- 21 Jan 2024 Genentech plans a phase-I trial (In volunteers) in USA (IV) in February 2024 (ISRCTN18049481)
- 21 Jan 2024 Preclinical trials in Infections in USA (IV) prior to January 2024